Product patent and process patent — Intellectual Property Rights I Notes

Product patent and process patent

The difference between owning “the pill” and owning “the way to make the pill” decided the fate of India’s generic-medicine industry. Before 2005 India gave only the second; after 2005 it gives both.

The distinction

A process patent protects only the method of making a product. A rival who reaches the same product by a different method does not infringe. This is weaker protection.
A product patent protects the product itself, however it is made. Any rival making that product — by any method — infringes. This is stronger protection.

Why it matters in India. Under the old s.5 of the 1970 Act, food, medicine and chemical inventions could get only process patents — deliberately, to keep medicines cheap by letting Indian firms make patented drugs by alternative processes. The 2005 amendment deleted s.5, introducing product patents for these fields to comply with TRIPS Article 27 (patents in all fields of technology).

TRIPS Agreement, 1994, Art. 27(1): “patents shall be available for any inventions, whether products or processes, in all fields of technology, provided that they are new, involve an inventive step and are capable of industrial application.”

In Simple Terms: A process patent guards the recipe; a product patent guards the dish no matter whose recipe made it. India switched from recipe-only (for drugs and food) to guarding the dish itself in 2005.

🧩 WORKED EXAMPLE — same molecule, different route

Facts. Company A holds a process patent for making a drug by Route 1. Company B makes the identical drug by Route 2.

Rule. A process patent protects only the claimed process; a different process reaching the same product does not infringe.

Apply. B used Route 2, not A’s Route 1, so B does not infringe A’s process patent — even though the product is identical. Had A held a product patent, B would infringe regardless of route.

Conclusion. Under a process patent B is free; the example shows exactly why product patents are stronger and why 2005 mattered.

flowchart TD
    KIND["Kinds of patent claim"]:::root
    KIND --> PR["Process patent — protects the method only"]:::leaf
    KIND --> PD["Product patent — protects the product, any method"]:::leaf
    PR --> WEAK["Different route = no infringement"]:::leaf
    PD --> STRONG["Any route making the product = infringement"]:::leaf
    classDef root fill:#FFF8DC,stroke:#000,color:#000;
    classDef leaf fill:#E6F3FF,stroke:#1E3A8A,color:#000;

Case Laws

Novartis AG v Union of India (2013) — arose directly from the post-2005 product-patent regime and the s.3(d) limit on it.
F. Hoffmann-La Roche v Cipla (2012) — enforcement of a product patent, illustrating its “any method” reach.

📄 Full notes + Question Bank (₹199) — every topic in depth, model answers to all past KSLU questions, in one printable PDF. Get the bundle · 10 Solved Problems · All Intellectual Property Rights I topics